AIM
HZNP

Arcadia Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Arcadia Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-948
Closed -$14K – 455
2017
Q1 		$14K Buy
+948
New +$15.4K ﹤0.01% 354

Other funds holding HZNP

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Arcadia Investment Management's HZNP Position: Q2 2017 in Review

Arcadia Investment Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2017, closing a stake of 948 shares — an estimated $14K sold.

Arcadia Investment Management first reported a position in HZNP in Q1 2017 and held it in 1 quarter. The position peaked at $14K in Q1 2017. 190 funds tracked by Wall St. Rank hold HZNP as of Q2 2017.

  • Arcadia Investment Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2017 after selling out during the quarter.
  • Arcadia Investment Management sold 948 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2017, an estimated $14K.
  • Arcadia Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2017 and held it in 1 quarter.
  • Arcadia Investment Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $14K in Q1 2017.
  • 190 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2017.

Based on Arcadia Investment Management's 13F filing for Q2 2017, filed 3 Aug 2017.